The company will hold its Q4 and full-year 2025 earnings call in February, with analysts expecting a double-digit decline in bottom-line results. Its foundation granted $2.6 million to expand a maternal diabetes program in NYC. The company is also involved in a new affordable senior housing development in Maine. Recent stock performance showed a 1.6% increase over the past month, but some analysis questions if weak financials could correct the share price. The company expects over $50 billion in specialty revenue for fiscal 2026.